A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Inclusion Criteria

Pathologic biopsy proven adenocarcinoma of the prostate

At least one of the following criteria:

cN1 on conventional or PET imaging
Grade group 5
Grade group 4
Grade group 3 and PSA ≥20 ng/mL
High probability of Radiographic T3 on MRI AND Grade group ≥2
Grade Group 3 AND PSA ≥10 ng/mL AND ≥50% positive biopsy cores
Age ≥ 18
ECOG < 1
Adequate organ and marrow function as defined per protocol.
Use of highly effective contraception (e.g. condoms) for the duration of treatment and a minimum of 90 days thereafter. Men must also agree not to donate sperm for the duration of the study participation, and for at least 90 days thereafter.
International Prostate Symptoms Score (IPSS) ≤ 20
Medically fit for treatment and agreeable to follow-up
Ability to understand and the willingness to sign a written informed consent
Tissue available for MiOncoSeq testing to assign DNA repair deficiency status

Exclusion Criteria

Clinical or radiographic evidence of distant metastatic disease by CT/bone scan
Clinical or radiographic evidence of high probability of clinical T4 disease
Prostate gland size >80 cc measured by ultrasound or MRI
Prominent median lobe assessed by treating physician
Lack of tissue from biopsy to be sent for correlative studies
Any prior treatment for prostate cancer (incudes history of TURP within 5 years of enrollment, chemotherapy, radiation therapy, or anti-androgen therapy)
Prohibited within 30 days prior to administration to study treatment: spironolactone and other investigational drug therapies.
Prohibited 3 months before participant registration and during administration of study treatment: non-steroidal anti-androgens (e.g., bicalutamide, flutamide, nilutamide), steroidal antiandrogens (megestrol acetate, cyproterone acetate), oral ketoconazole, chemotherapy, immunotherapy, estrogens, radiopharmaceuticals.
History of prior pelvic radiation therapy
Concurrent treatment with strong CYP3A4 inducers such as phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital
Enrollment concurrently in another investigational drug study within 1 month of registration
History of another active malignancy within the previous 3 years except for adequately treated skin cancer or superficial bladder cancer
History of or active Crohn's disease or ulcerative colitis
Contraindication to or inability to tolerate MRIs
Patients with severe depression
Uncontrolled diabetes or known HbA1c>10
Any gastrointestinal disorder affecting absorption
Active pituitary or adrenal dysfunction
Patients with significant cardiovascular disease potentially including severe / unstable angina, recent history of myocardial infarction, clinically significant heart failure, cerebrovascular disease, venous thromboembolic events, clinically significant arrhythmias)
Uncontrolled hypertension with persistently elevated systolic blood pressure >160 mmgHg or diastolic blood pressure >100 mmHg despite anti-hypertensive agents.
Prolonged QTc >450 ms or any ECG changes that interfere with QT interval interpretation
Major surgery within 1 month of registration
History of myelodysplastic syndrome or leukemia
A known hypersensitivity to niraparib, abiraterone acetate, leuprolide, and/or prednisone
Active infection or other medical condition that would be a contraindication to prednisone use
Patients with known active hepatitis or chronic liver disease including cirrhosis
Any condition that in the opinion of the investigator would preclude participation in this study